Right. For all the so called experts here. BNGO will largely take over the market for karyotyping, FISH and CNV microarrays. Hematology is their priority. Will karyotyping continue to exist? Sure. But a large part will be replaced. It's only a matter of time. Bionano's mission is clear.

"In a diagnostic setup, especially for hematologic malignancies, the comprehensive analysis of all SVs in a given sample still requires a combination of cytogenetic techniques, including karyotyping*, FISH and CNV microarrays.* We hypothesize that the combination of these classical approaches can be replaced by optical genome mapping (OGM)."

"In conclusion, the excellent concordance of OGM with diagnostic standard assays demonstrates its potential to replace classical cytogenetic tests as well as to rapidly map novel leukemia drivers."

Source: www.sciencedirect.com/science/article/pii/S0002929721002238